Business Wire

Simple blood test combined with exacerbation history may help to identify when to add ICS to COPD treatment

Del

Boehringer Ingelheim today announced a new post-hoc subanalysis of the WISDOM study that suggests only 4 out of 100 people with chronic obstructive pulmonary disease (COPD), who have a history of frequent exacerbations and raised eosinophil levels (≥400 cells/µL), may further benefit by adding inhaled corticosteroids (ICS, fluticasone propionate 500µg twice daily) to Spiriva® (tiotropium 18μg once daily) and a long-acting beta2-agonist (LABA, salmeterol 50μg twice daily) with regard to reducing exacerbation risk.1,3 Eosinophils, which are a type of white blood cell, are assessed as part of a routine blood test.4 This new post-hoc subanalysis was presented today at the European Respiratory Society (ERS) International Congress 2016 in London.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160905005424/en/

New considerations for inhaled corticosteroids (ICS) use in chronic obstructive pulmonary disease (C ...

New considerations for inhaled corticosteroids (ICS) use in chronic obstructive pulmonary disease (COPD)(Graphic: Business Wire)

“New results from the WISDOM study indicate that using ICS as part of a triple therapy regimen in COPD maintenance treatment reduces the likelihood of an exacerbation for a smaller number of people than previously thought. It challenges our current understanding of the appropriate use of ICS in COPD maintenance therapy,” said study investigator Professor Peter Calverley, Professor of Pulmonary Medicine, University of Liverpool, UK. “These study results add important information to a debate that has potentially wide-ranging implications for the future treatment of people with COPD.”

Exacerbations significantly contribute to the impact of COPD, often leading to the person being admitted to a hospital,5 and can increase the risk of death.6 The Global Initiative for Chronic Obstructive Lung Disease (GOLD), which is a collaboration between the World Health Organization and the US National Institutes of Health, recommends the use of ICS-containing therapy only in people with COPD who have severe to very severe lung function impairment and/or are at high risk of exacerbations (GOLD C/D) or who have had a hospitalisation7 – the patient population studied in WISDOM. However, ICS are widely used outside of GOLD treatment recommendations in combination with bronchodilators, such as tiotropium and LABAs, in the treatment of COPD.8

This new post-hoc subanalysis suggests that by combining history of frequent exacerbations (two or more exacerbations in the past twelve months) with raised blood eosinophil levels of ≥400 cells/µL, healthcare providers may more precisely identify the minority of people with COPD who could experience a further exacerbation risk reduction from ICS (fluticasone propionate) on top of tiotropium and a LABA (salmeterol).1,3

This finding further builds on an earlier post-hoc analysis of the WISDOM trial, which evaluated blood eosinophil levels alone, and indicated that people with blood eosinophil levels higher than ≥300 cells/µL had an additional exacerbation reduction from ICS (fluticasone propionate) on top of tiotropium and a LABA (salmeterol).2

The 52-week WISDOM study (NCT00975195) evaluated the effect of ICS (fluticasone propionate) withdrawal in people with severe to very severe COPD having a history of exacerbation, while receiving tiotropium and a LABA (salmeterol).9 The patient population of the WISDOM trial represents approximately 20 percent of the normal COPD patient population10 and only 4 percent of this population were known to have a history of frequent exacerbations (two or more exacerbations in the past twelve months) with raised blood eosinophil levels of ≥400 cells/µL.1,3

“Boehringer Ingelheim is committed to continuing scientific research that informs the optimal treatment of people with COPD. These findings add to our understanding of the factors that should be considered by healthcare providers when deciding a treatment regimen for people with COPD – specifically when to add an ICS,” said Dr William Mezzanotte, Vice President and Head of Respiratory Medicine at Boehringer Ingelheim. “In addition, these findings highlight the importance of further investigation and discussion of this topic.”

In the WISDOM study population, complete ICS (fluticasone propionate) withdrawal was associated with a small reduction in trough FEV1.9 The earlier post-hoc analysis showed overall no relationship between blood eosinophil count and change in lung function with ICS (fluticasone propionate) withdrawal.2 However, the latest post-hoc subanalysis indicated a relevant reduction in trough FEV1 in the small subgroup of people with high eosinophil count and frequent exacerbations.11

COPD is a serious but manageable lung disease, which is estimated to affect 210 million people worldwide.12 Total deaths from COPD are projected to increase by more than 30 percent in the next 10 years; COPD is predicted to become the third leading cause of death globally by 2030.13

For ‘Notes to Editors’ and ‘References’ please visit: https://www.boehringer-ingelheim.com/press-release/simple-blood-test-help-to-identify-when-to-add-ics

Contact information

Boehringer Ingelheim
Corporate Communications
Media + PR
Carolin Grob
Email: carolin.grob@boehringer-ingelheim.com
Phone: +49 (6132) 77-182603
Fax: +49 (6132) 77-6601
Email: press@boehringer-ingelheim.com
www.boehringer-ingelheim.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Koza Altin Welcomes Court’s Rejection of Akin Ipek’s Share Purchase Agreement13.7.2018 15:58Pressemelding

A Turkish Court has found against businessman Akin Ipek this week – ruling that a share purchase agreement, which he had submitted as vital evidence in support of his case against the Turkish state, is null and void. The matter was brought to the Ankara Commercial Court in March 2017 by Koza Holding (parent company of Koza Altin) which, according to Mr Ipek’s share purchase agreement, purportedly transferred all of its shares to Ipek Investment Limited. Koza Holding filed the lawsuit for legal recognition that the share purchase agreement is void. The ruling in Turkey follows on from an earlier judgment set down by the English High Court, which rejected Mr Ipek’s attempt to use up to £3m of UK subsidiary Koza Ltd’s money to fund a claim against the Turkish State at the International Centre for Settlement of Investment Disputes (ICSID). In the English ruling, Deputy Judge Richard Spearman QC declared the “authenticity” of the share purchase agreement as “open to very serious doubt”. The

Mindbreeze Positioned in the Leaders Quadrant of the Gartner’s 2018 Magic Quadrant for Insight Engines13.7.2018 15:27Pressemelding

Mindbreeze, a leading global provider of appliances and cloud services for information insight and applied artificial intelligence with a focus on knowledge management for leading international companies, announced today that Gartner, Inc. has positioned Mindbreeze in the Leaders quadrant of the 2018 Magic Quadrant for Insight Engines. Mindbreeze is positioned highest on the ability to execute axis. The research and advisory firm Gartner, Inc. evaluated 13 different providers from all over the world. “Understanding the meaning of information is a key priority for today’s customers. Mindbreeze InSpire leverages the full power of our sophisticated AI engine to provide actionable insights and answers ̶ not just more data. Seeing our position in the Magic Quadrant, my first reaction was ‘AWESOME’. Insight Engine was positioned the highest on the ability to execute axis and we believe that's exactly what sets us apart from our competitors. We made the bold move to focus on product innovatio

H.I.G. Capital Announces the Sale of Kondor13.7.2018 14:06Pressemelding

H.I.G. Capital (“H.I.G.”), a leading global private equity investment firm with more than €20 billion of equity capital under management, announced today that one of its affiliates has sold Kondor Limited, a specialist provider of category management solutions for audio and mobile accessory products into the retail and mobile network channels in the UK and Europe, to DCC Technology (which principally trades under the Exertis brand), part of DCC plc, the leading international sales, marketing and support services group. Terms of the transaction were not disclosed. Headquartered in Dorset, England, Kondor distributes audio and mobile accessory products to a broad range of e-tail, retail and mobile operator customers. H.I.G. invested in Kondor in 2014, and has since overseen a full reorganisation of the business. H.I.G. worked in partnership with Kondor to professionalise back office systems, develop Kondor’s access to market data, optimise the company’s product range, improve stock manag

Contactless Technology Powers Fifty Percent of Purchases at 2018 FIFA World Cup Russia™13.7.2018 09:00Pressemelding

Visa (NYSE: V), the Official Payment Services Partner of FIFA, today released an analysis of spending inside the 2018 FIFA World Cup Russia™ stadiums from the opening match on June 14 through the semi-finals on July 11. The data highlights the increased consumer adoption of innovative payment technology, as fifty percent of purchases with Visa in tournament venues utilized contactless transactions, including cards, mobile devices and wearables. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180713005025/en/ For the 2018 FIFA World Cup Russia™, Visa is the exclusive payment service in all stadiums where payment cards are accepted. In-stadium, fans can pay with contactless Visa credit and debit cards and mobile payment services at the more than 3,500 point-of-sale terminals and 1,000 mobile concessionaires that have been equipped with the latest in payment innovation. (Photo: Business Wire) Visa cardholders on average spent 1,

Brazil Approves AerSafe for Airbus 321 Aircraft to Comply with Fuel Tank Flammability Reduction Rule12.7.2018 19:18Pressemelding

AerSale ® announced today that the National Civil Aviation Agency of Brazil (ANAC) has approved the Federal Aviation Administration’s (FAA’s) Supplemental Type Certificate (STC) for the company’s AerSafe™ system on Airbus 321 aircraft (ST04010NY), that complies with the Fuel Tank Flammability Reduction (FTFR) rule. This is the second ANAC STC approval for AerSafe, following approval on Boeing 737 CL aircraft in 2017. In the coming months, AerSafe will be expanded to cover additional aircraft types, to meet the September 2019 deadline of the ANAC regulation, Regulamento Brasileiro da Avaiação Civil (RBAC) nº 121.1117, that applies specifically to passenger aircraft that fly within or into Brazil. AerSale’s STCs for the Boeing 737 CL and NG series (ST02980NY) and Boeing 767 series (ST03599NY) have already been approved by the FAA. “We are pleased that our Latin American customers operating A320 family aircraft are now able to immediately benefit from AerSafe’s numerous advantages,” said

Blockchain-based Adents NovaTrack Issues Token to Standardize Access to Comprehensive Supply Chain Traceability12.7.2018 18:20Pressemelding

Adents, leading serialization and track & trace solutions provider, announces the issue of tokens that, combined with its NovaTrack platform, will standardize access to full supply chain traceability. Adents recently released Adents NovaTrack, a marriage of technologies co-developed with Microsoft. The solution utilizes Blockchain, A.I., IoT and serialization functionalities that, when combined, bring comprehensive visibility throughout product distribution chains & life cycles. The result is a solution highly mindful not only in terms of performance and security, but also governance and scalability. With NovaTrack, Adents aims to create an ecosystem of consortium-based blockchains independent from each other, and individually launched on-demand by various supply chain stakeholders (brands, manufacturers, logistics professionals, etc.). Each consortium-based blockchain will provide a secure environment to its participants to share supply chain data and processes. From brands, manufactu